The extraordinary meeting, scheduled for November 14th, follows a disagreement between the board and majority shareholder the Novo Nordisk Foundation.
After failing to reach an understanding "the board concluded that it is in the best interest of the company and its shareholders to convene an extraordinary general meeting to elect new board members to provide clarity on the future governance of Novo Nordisk," board chair Helge Lund said in a statement.
Pharmaceutical giant Novo announced in September that it would cut 11 percent of its workforce, including 5,000 jobs in Denmark, as the maker of Ozempic and Wegovy faces rising competition for its anti-obesity treatments.
The drug maker said it would save eight billion kroner by slashing 9,000 jobs in total across the company.
The company has lowered its earnings forecast -three times this year and now expects operating profit growth of between four and 10 percent, down from 10-16 percent previously.
Comments